OBJECTIVES: To estimate the economic impact in the treatment of Colombian patients with Non-Hodgkin lymphoma developing a time and motion study for the IV administration versus subcutaneous (SC) presentation of rituximab. METHODS: Time and motion study, observational, multicentric (two private hospitals, one public hospital), non-interventional describing costs and times from the admission of the patient until their discharge, recording healthcare professionals (HPC), drugs, consumables and procedures room. Population evaluated were patients in first chemotherapy with rituximab IV with diffuse large B-cell lymphoma and follicular lymphoma, in regular cycles and in maintenance phase. Finally, we calculated the time and cost differences of the treatment of patients with SC (drug still non approved in Colombia, therefore these data was obtained from Rule et al., 2014) instead IV rituximab from the perspective of the provider.  RESULTS: Patients were treated with rituximab IV at doses between 520 mg and 700 mg. If they had been treated with SC, it estimated to cause net savings of $360 USD per patient, which were represented in costs of healthcare professionals (HPC), drugs, consumables and procedures room and around 207 minutes of total time expenditure. The cost of rituximab SC is the most important savings factor to the provider because it is administrated at constant doses non-weight depended.    CONCLUSIONS: Rituximab SC was a cost-saving strategy for the providers compared with Rituximab IV. As results of the savings in cost of treatment, consumables, procedures room and total time expenditure, the actual resources of the health provider could be optimized.